Credit Suisse Starts Akebia Therapeutics (AKBA) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- Wall St set for higher open as soft inflation data eases rate-hike fears
- Equity positioning stays overweight, but summer extremes have eased: Barclays
- Oil gains as stalled US-Iran talks trump supply recovery
- Micron reports Q4 today: Why Lynx Equity sees massive upside
- Moderna: Citi says oncology optimism is priced in, cuts rating to sell
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- S&P 500 flat as higher bond yields counter tech optimism
- HPE raises networking revenue outlook, secures $1.2B Vultr order
- Mattel names Roger Lynch as chairman and CEO, replacing Ynon Kreiz
Akebia Therapeutics (AKBA) Surges as Wall Street Screams 'Buy'
April 14, 2014 3:39 PM EDTAkebia Therapeutics (NASDAQ: AKBA) is zooming higher in mid-day trade as momentum traders jump on the name amid positive analysts coverage and aggressive prices targets from four Wall Street firms... More
UPDATE: UBS Starts Akebia Therapeutics (AKBA) at Buy
April 14, 2014 8:14 AM EDT(Updated - April 14, 2014 1:37 PM EDT)
UBS initiated coverage on Akebia Therapeutics (NASDAQ: AKBA) with a Buy rating and a price target of $28.00.
Analyst Matthew Roden said, "Key tenets of our Buy thesis: [1] HIF... More
Morgan Stanley Starts Akebia Therapeutics (AKBA) at Overweight w/PT of $90
April 14, 2014 8:13 AM EDTMorgan Stanley initiated coverage on Akebia Therapeutics (NASDAQ: AKBA) with an Overweight rating and a price target of $90.
Analyst David Friedman said "We see Akebias lead asset, AKB-6548, as having $2+bn... More
Nomura Securities Starts Akebia Therapeutics (AKBA) at Buy
April 14, 2014 7:47 AM EDTNomura Securities initiates coverage on Akebia Therapeutics (NASDAQ: AKBA) with a Buy rating and a price target of $39.00.
Analyst , M. Ian Somaiya said, "We believe Akebias AKB-6548 represents a compelling treatment option for anemia due to chronic kidney disease (CKD), a $6bn-plus... More
